Scott M. Rocklage, Ph.D., is currently a managing partner at 5AM Ventures. He joined the organization as a Venture Partner in 2003 and was promoted to his current position a year later. Dr. Rocklage holds a Chemistry B.S from the University of California, Berkeley, as well as a chemistry Ph.D. from the Massachusetts Institute of Technology (MIT). While at MIT, he did research in the laboratory belonging to Richard R. Schrock who won the Chemistry Nobel Prize in 2005.
Dr. Scott Rocklage has an experience of over three decades in healthcare management. His strategic responsibilities in leadership have resulted in approval of three United States New Drug Applications by FDA. He has gained this expertise and experience in health management by serving in numerous top positions in the industry. For instance, from May 2016 to July 2016, the doctor served as the Chief Executive Officer in EPIRUS Biopharmaceuticals. Before this, he had also served as the acting Chief Executive Officer in the same company a week before being promoted from the acting capacity.
Dr. Rocklage has served as president in several corporations. He served as both President and Chief Executive Officer at Amersham Health, as well as Co-President in Ilypsa, Inc (acquired by Amgen). The doctor has been the Founding Chief Executive Officer as well as President of Cubist Pharmaceuticals Inc from July 1994 to March 2001. Dr. Rocklage was also President, Chairman and Chief Executive Officer of Nycomed International in the 1992-1994 period.
Other than being President and Chief Executive Officer in the different corporations, Dr. Rocklage has served in several R&D positions at Catalytica and Salutar Pharmaceuticals. The good doctor has chaired the Board at Cidara Therapeutics since 2013. He has also been the Chairman of Novira Therapeutics, Inc. from August 2012. To know more click here.
Currently, Dr. Rocklage chairs the board of Rennovia Inc, Cidara, and Kinestral as well as the boards of Pulmatrix and Epirus. Additionally, the doctor is the board chairman of Semprus, Achaogen, Relypsa. He is also the Chairman of the Whitehead Institute’s Board of Associates. He owns over 100 peer-reviewed publications as well as over 30 United States patents. Dr. Rocklage has a Food and Drug Administration approval of several drugs. His office is based in Boston, Massachusetts.